• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".

作者信息

Kim Beom Kyung

机构信息

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Clin Mol Hepatol. 2024 Oct;30(4):656-658. doi: 10.3350/cmh.2024.0499. Epub 2024 Jul 8.

DOI:10.3350/cmh.2024.0499
PMID:38973181
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11540388/
Abstract
摘要

相似文献

1
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".乙型肝炎抗病毒治疗期间肝癌预测模型性能下降：还需谨记哪些要点：关于“慢性乙型肝炎患者长期抗病毒治疗导致肝细胞癌预测模型性能下降”的社论
Clin Mol Hepatol. 2024 Oct;30(4):656-658. doi: 10.3350/cmh.2024.0499. Epub 2024 Jul 8.
2
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.长期抗病毒治疗会降低慢性乙型肝炎患者肝细胞癌预测模型的性能。
Clin Mol Hepatol. 2023 Jul;29(3):747-762. doi: 10.3350/cmh.2023.0121. Epub 2023 May 10.
3
Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.未接受抗病毒治疗的乙型肝炎病毒患者肝细胞癌累积发病率的长期随访。
World J Gastroenterol. 2021 Mar 21;27(11):1101-1116. doi: 10.3748/wjg.v27.i11.1101.
4
Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.改良 PAGE-B 评分可预测接受抗病毒治疗的亚洲慢性乙型肝炎患者发生肝细胞癌的风险。
J Hepatol. 2018 Nov;69(5):1066-1073. doi: 10.1016/j.jhep.2018.07.018. Epub 2018 Aug 1.
5
Correspondence to editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".致关于“慢性乙型肝炎患者长期抗病毒治疗后肝细胞癌预测模型性能下降”的社论的信函。
Clin Mol Hepatol. 2024 Oct;30(4):994-996. doi: 10.3350/cmh.2024.0552. Epub 2024 Jul 23.
6
[Risk assessment and management of hepatocellular carcinoma occurrence in patients with chronic hepatitis B in the era of antiviral therapy].[抗病毒治疗时代慢性乙型肝炎患者肝细胞癌发生的风险评估与管理]
Zhonghua Gan Zang Bing Za Zhi. 2021 Apr 20;29(4):297-300. doi: 10.3760/cma.j.cn501113-20210409-00175.
7
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.纳入中度乙肝病毒脱氧核糖核酸水平的PAGE-B可预测HBeAg阳性慢性乙型肝炎患者发生肝细胞癌的风险。
J Hepatol. 2024 Jan;80(1):20-30. doi: 10.1016/j.jhep.2023.09.011. Epub 2023 Sep 19.
8
Risk prediction models for hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy: A meta-analysis.抗病毒治疗的慢性乙型肝炎患者肝细胞癌风险预测模型：荟萃分析。
Clin Res Hepatol Gastroenterol. 2022 Jun-Jul;46(6):101930. doi: 10.1016/j.clinre.2022.101930. Epub 2022 Apr 20.
9
Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients.接受抗病毒治疗的慢性乙型肝炎患者肝细胞癌的长期预测模型：基于韩国患者的数据。
J Clin Med. 2022 Nov 8;11(22):6613. doi: 10.3390/jcm11226613.
10
Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Receiving Finite Periods of Antiviral Therapy.预测接受有限疗程抗病毒治疗的慢性乙型肝炎患者的肝细胞癌风险
Cancers (Basel). 2023 Jun 25;15(13):3343. doi: 10.3390/cancers15133343.

引用本文的文献

1
Prediction Model for Familial Aggregated HBV-Associated Hepatocellular Carcinoma Based on Serum Biomarkers.基于血清生物标志物的家族聚集性乙肝相关肝细胞癌预测模型
Cancer Rep (Hoboken). 2025 Jun;8(6):e70253. doi: 10.1002/cnr2.70253.
2
Reply to correspondence on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".对关于“慢性乙型肝炎患者长期抗病毒治疗后肝细胞癌预测模型性能下降”的通信的回复
Clin Mol Hepatol. 2024 Oct;30(4):1044-1046. doi: 10.3350/cmh.2024.0584. Epub 2024 Jul 29.
3
Correspondence to editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".致关于“慢性乙型肝炎患者长期抗病毒治疗后肝细胞癌预测模型性能下降”的社论的信函。
Clin Mol Hepatol. 2024 Oct;30(4):994-996. doi: 10.3350/cmh.2024.0552. Epub 2024 Jul 23.

本文引用的文献

1
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study.代谢功能障碍相关脂肪性肝病和/或酒精所致肝癌风险：一项全国性研究
Am J Gastroenterol. 2025 Feb 1;120(2):410-419. doi: 10.14309/ajg.0000000000002920. Epub 2024 Jun 27.
2
Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection.利用深度学习算法的 CT 分析对慢性乙型肝炎病毒感染患者的预后作用。
Clin Mol Hepatol. 2023 Oct;29(4):1029-1042. doi: 10.3350/cmh.2023.0190. Epub 2023 Aug 29.
3
Five-year on-treatment variables-based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients.基于治疗五年变量的PPACS模型可预测恩替卡韦/替诺福韦治疗患者后续发生肝细胞癌的情况。
Int J Cancer. 2023 Dec 15;153(12):2045-2054. doi: 10.1002/ijc.34704. Epub 2023 Aug 24.
4
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy.接受抗病毒治疗的乙型肝炎病毒相关肝细胞癌患者的预测模型
J Formos Med Assoc. 2023 Dec;122(12):1238-1246. doi: 10.1016/j.jfma.2023.05.029. Epub 2023 Jun 15.
5
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.长期抗病毒治疗会降低慢性乙型肝炎患者肝细胞癌预测模型的性能。
Clin Mol Hepatol. 2023 Jul;29(3):747-762. doi: 10.3350/cmh.2023.0121. Epub 2023 May 10.
6
Association of Alcohol Consumption With Liver Cancer and All-Cause Mortality in Chronic Hepatitis B Patients Without Cirrhosis.无肝硬化慢性乙型肝炎患者饮酒与肝癌及全因死亡率的关联
Clin Gastroenterol Hepatol. 2023 Nov;21(12):3191-3194.e3. doi: 10.1016/j.cgh.2023.02.025. Epub 2023 Mar 3.
7
The role of different viral biomarkers on the management of chronic hepatitis B.不同病毒标志物在慢性乙型肝炎管理中的作用。
Clin Mol Hepatol. 2023 Apr;29(2):263-276. doi: 10.3350/cmh.2022.0448. Epub 2023 Jan 19.
8
Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints.14 种 HCC 预测模型在 CHB 中的比较性能：在治疗过程中的连续时间点的动态验证。
Am J Gastroenterol. 2022 Sep 1;117(9):1444-1453. doi: 10.14309/ajg.0000000000001865. Epub 2022 Jun 10.
9
External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study.使用慢性乙型肝炎患者无创纤维化标志物治疗期间变化对FSAC模型进行外部验证：一项多中心研究
Cancers (Basel). 2022 Jan 29;14(3):711. doi: 10.3390/cancers14030711.
10
Prediction of Hepatocellular Carcinoma by On-Therapy Response of Noninvasive Fibrosis Markers in Chronic Hepatitis B.基于慢性乙型肝炎患者治疗中无创伤性纤维化标志物的应答预测肝细胞癌。
Am J Gastroenterol. 2021 Aug 1;116(8):1657-1666. doi: 10.14309/ajg.0000000000001219.